Literature DB >> 10980486

Simultaneous intrastriatal and intranigral dopaminergic grafts in the parkinsonian rat model: role of the intranigral graft.

K A Baker1, D Sadi, M Hong, I Mendez.   

Abstract

The current transplantation strategy in experimental and clinical Parkinson's disease (PD) has been to place nigral dopaminergic grafts not in their ontogenic site (substantia nigra) but in their target area (striatum). Although intrastriatal dopaminergic grafts are capable of reinnervating the striatum, they fail to reinnervate the nigra, which may be an important factor limiting the efficacy of fetal tissue transplantation in parkinsonian patients. We have previously shown that simultaneous intrastriatal and intranigral dopaminergic grafts (double grafts) may provide a more complete restoration of the nigrostriatal circuitry (Mendez et al. [1996] J Neurosci 16:7216-7227; Mendez and Hong [1997] Brain Res 778:194-205). In the present study, we investigated the contribution of the intranigral graft to functional recovery in double-grafted hemiparkinsonian rats. Twenty Wistar rats with unilateral 6-hydroxydopamine (6-OHDA) lesions of the nigrostriatal pathway were divided into two groups and received either double grafts (n = 10) or intrastriatal grafts alone (n = 10). Following transplantation, both intrastriatally and double-grafted animals had a significant decrease in rotational behavior. However, only animals with double grafts exhibited a significant increase in contralateral adjusting step performance. The intranigral graft was subsequently lesioned by a second 6-OHDA injection. Following the second lesion, animals with double grafts exhibited a significant reversal of rotational behavior and a 51% reduction in contralateral adjusting step performance. The reversal in functional recovery correlated with a significant loss of intranigral grafted neurons. These results suggest that the intranigral graft has an important role in the functional recovery of double-grafted animals. Restoration of dopaminergic innervation to both the nigra and the striatum may be crucial for optimizing graft efficacy and may be a superior strategy in neural transplantation for PD. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10980486

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  11 in total

1.  Engraftment and differentiation of embryonic stem cell-derived neural progenitor cells in the cochlear nerve trunk: growth of processes into the organ of Corti.

Authors:  C Eduardo Corrales; Luying Pan; Huawei Li; M Charles Liberman; Stefan Heller; Albert S B Edge
Journal:  J Neurobiol       Date:  2006-11

Review 2.  Emerging regenerative medicine and tissue engineering strategies for Parkinson's disease.

Authors:  James P Harris; Justin C Burrell; Laura A Struzyna; H Isaac Chen; Mijail D Serruya; John A Wolf; John E Duda; D Kacy Cullen
Journal:  NPJ Parkinsons Dis       Date:  2020-01-08

3.  Delivery of chemotropic proteins and improvement of dopaminergic neuron outgrowth through a thixotropic hybrid nano-gel.

Authors:  Elisa Tamariz; Andrew C A Wan; Y Shona Pek; Magda Giordano; Genoveva Hernández-Padrón; Alfredo Varela-Echavarría; Iván Velasco; Víctor M Castaño
Journal:  J Mater Sci Mater Med       Date:  2011-07-09       Impact factor: 3.896

4.  Enhancement of sensorimotor behavioral recovery in hemiparkinsonian rats with intrastriatal, intranigral, and intrasubthalamic nucleus dopaminergic transplants.

Authors:  K Mukhida; K A Baker; D Sadi; I Mendez
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

5.  Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease.

Authors:  Ivar Mendez; Rosario Sanchez-Pernaute; Oliver Cooper; Angel Viñuela; Daniela Ferrari; Lars Björklund; Alain Dagher; Ole Isacson
Journal:  Brain       Date:  2005-05-04       Impact factor: 13.501

6.  Disruption of mitochondrial complex I induces progressive parkinsonism.

Authors:  Patricia González-Rodríguez; Enrico Zampese; Kristen A Stout; Jaime N Guzman; Ema Ilijic; Ben Yang; Tatiana Tkatch; Mihaela A Stavarache; David L Wokosin; Lin Gao; Michael G Kaplitt; José López-Barneo; Paul T Schumacker; D James Surmeier
Journal:  Nature       Date:  2021-11-03       Impact factor: 69.504

7.  Comparison of Human Primary with Human iPS Cell-Derived Dopaminergic Neuron Grafts in the Rat Model for Parkinson's Disease.

Authors:  Su-Ping Peng; Sjef Copray
Journal:  Stem Cell Rev Rep       Date:  2016-02       Impact factor: 5.739

Review 8.  Emerging regenerative medicine and tissue engineering strategies for Parkinson's disease.

Authors:  James P Harris; Justin C Burrell; Laura A Struzyna; H Isaac Chen; Mijail D Serruya; John A Wolf; John E Duda; D Kacy Cullen
Journal:  NPJ Parkinsons Dis       Date:  2020-01-08

9.  Better Outcomes with Intranigral versus Intrastriatal Cell Transplantation: Relevance for Parkinson's Disease.

Authors:  Marine Droguerre; Sébastien Brot; Clément Vitrac; Marianne Benoit-Marand; Laure Belnoue; Maelig Patrigeon; Anaïs Lainé; Emile Béré; Mohamed Jaber; Afsaneh Gaillard
Journal:  Cells       Date:  2022-04-01       Impact factor: 6.600

Review 10.  Restoring lost nigrostriatal fibers in Parkinson's disease based on clinically-inspired design criteria.

Authors:  Wisberty J Gordián-Vélez; Dimple Chouhan; Rodrigo A España; H Isaac Chen; Jason A Burdick; John E Duda; D Kacy Cullen
Journal:  Brain Res Bull       Date:  2021-07-28       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.